"Luo attributed the IPO drought—and Alamar's ability to end it—to a long-awaited technological breakthrough in early disease detection of cancer and Alzheimer's. The company's platform can detect disease signals in blood that are too faint for existing tools to pick up."
"Much like Kailera, Alamar shares soared, up 33% on the first day of trading. The listing carries symbolic weight as the life sciences tools and diagnostics sector has been effectively shut out of the public markets since 2021."
Yuling Luo rang the Nasdaq closing bell after Alamar Biosciences' IPO, which was oversubscribed. This week saw two significant biotech IPOs, indicating renewed investor interest in life sciences. Kailera Therapeutics raised $625 million, marking a record for biotech IPOs. Alamar raised $191.3 million, with shares rising 33% on the first trading day. The life sciences tools sector had been inactive since 2021, but technological advancements in early disease detection have reignited interest, allowing Alamar to break the IPO drought.
Read at Fortune
Unable to calculate read time
Collection
[
|
...
]